Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
That means creating a safe, encouraging space where your goals are heard and your wellness journey is celebrated
Fracture healing in the elderly patient
We already are having clients positioning themselves for it, says Jesse Dresser, a partner at Frier Levitt
Green tea extract (25 or 50 mg/kg i.p.) and catechin (50 or 100 mg/kg i.p.), administered for 7 days, reversed the immobility time correlated with increased GSH and decreased lipid peroxidation in brains of fatigued mice (Singal et al
When iodine levels are low, high levels of thyroglobulin can be found in the blood as iodine-poor thyroglobulin builds up and leaks from the thyroid into the bloodstream
